11:23 AM EST - Valeant Pharmaceuticals International, Inc. : Announced its full-year 2017 financial results. Revenues were $8.724 Billion, with GAAP Net Income of $2.404 Billion, GAAP Cash Flow from Operations of $2.290 Billion, and Adjusted EBITDA (non-GAAP) of $3.638 Billion. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading down $2.55 at $21.20.
